Cargando…
The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy
SIMPLE SUMMARY: Combining chemoradiotherapy with immunotherapy is one of the main milestones in cancer treatment. The optimal sequence to ensure the effectiveness of the treatment is unknown. We investigated the kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L), a multi-potential haemopoieti...
Autores principales: | Kuncman, Łukasz, Orzechowska, Magdalena, Stawiski, Konrad, Masłowski, Michał, Ciążyńska, Magdalena, Gottwald, Leszek, Milecki, Tomasz, Fijuth, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405787/ https://www.ncbi.nlm.nih.gov/pubmed/36010838 http://dx.doi.org/10.3390/cancers14163844 |
Ejemplares similares
-
Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
por: Kuncman, Łukasz, et al.
Publicado: (2020) -
FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020) -
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
por: Ramos, Maria I, et al.
Publicado: (2013) -
FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017) -
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)